EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

ADHD Pharmacotherapy and Mortality in Individuals With ADHD

Lin Li, Nanbo Zhu, Le Zhang, Ralf Kuja-Halkola, Brian M D'Onofrio, Isabell Brikell, Paul Lichtenstein, Samuele Cortese, Henrik Larsson, Zheng Chang

JAMA · 12.03.2024 · 331 (10) · 850

DOI: 10.1001/jama.2024.0851 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA, erschienen am 12.03.2024. Verfasst von Lin Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants. Die Arbeit wurde bisher 137-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Attention-deficit/hyperactivity disorder (ADHD) is associated with increased risks of adverse health outcomes including premature death, but it is unclear whether ADHD pharmacotherapy influences the mortality risk.

Objective

To investigate whether initiation of ADHD pharmacotherapy was associated with reduced mortality risk in individuals with ADHD. Design, Setting, and Participants In an observational nationwide cohort study in Sweden applying the target trial emulation framework, we identified individuals aged 6 through 64 years with an incident diagnosis of ADHD from 2007 through 2018 and no ADHD medication dispensation prior to diagnosis. Follow-up started from ADHD diagnosis until death, emigration, 2 years after ADHD diagnosis, or December 31, 2020, whichever came first. Exposures ADHD medication initiation was defined as dispensing of medication within 3 months of diagnosis. Main Outcomes and Measures We assessed all-cause mortality within 2 years of ADHD diagnosis, as well as natural-cause (eg, physical conditions) and unnatural-cause mortality (eg, unintentional injuries, suicide, and accidental poisonings).

Results

Of 148 578 individuals with ADHD (61 356 females [41.3%]), 84 204 (56.7%) initiated ADHD medication. The median age at diagnosis was 17.4 years (IQR, 11.6-29.1 years). The 2-year mortality risk was lower in the initiation treatment strategy group (39.1 per 10 000 individuals) than in the noninitiation treatment strategy group (48.1 per 10 000 individuals), with a risk difference of −8.9 per 10 000 individuals (95% CI, −17.3 to −0.6). ADHD medication initiation was associated with significantly lower rate of all-cause mortality (hazard ratio [HR], 0.79; 95% CI, 0.70 to 0.88) and unnatural-cause mortality (2-year mortality risk, 25.9 per 10 000 individuals vs 33.3 per 10 000 individuals; risk difference, −7.4 per 10 000 individuals; 95% CI, −14.2 to −0.5; HR, 0.75; 95% CI, 0.66 to 0.86), but not natural-cause mortality (2-year mortality risk, 13.1 per 10 000 individuals vs 14.7 per 10 000 individuals; risk difference, −1.6 per 10 000 individuals; 95% CI, −6.4 to 3.2; HR, 0.86; 95% CI, 0.71 to 1.05). Conclusions and Relevance Among individuals diagnosed with ADHD, medication initiation was associated with significantly lower all-cause mortality, particularly for death due to unnatural causes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsAdolescentAdultChildFemaleHumansYoung AdultCohort StudiesMortality, PrematureSwedenMiddle AgedMale

Substanzen

Central Nervous System Stimulants

Autor:innen und Institutionen

  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Psychological and Brain Sciences, Indiana University, Bloomington.
  • Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • Centre for Innovation in Mental Health-School of Psychology, Faculty of Environmental and Life Sciences, and Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, South…
  • New York University Child Study Center, Hassenfeld Children's Hospital at NYU Langone, New York.
  • Solent NHS Trust, Southampton, United Kingdom.

Zitieren

APA

Li, L., Zhu, N., Zhang, L., Kuja-Halkola, R., D'Onofrio, B. M., Brikell, I., Lichtenstein, P., Cortese, S., Larsson, H., & Chang, Z. (2024). ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA, 331(10), 850. https://doi.org/10.1001/jama.2024.0851

Vancouver

Li L, Zhu N, Zhang L, Kuja-Halkola R, D'Onofrio BM, Brikell I, et al. ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA. 2024;331(10):850. doi:10.1001/jama.2024.0851

BibTeX
@article{Li2024,
  author = {Li, Lin and Zhu, Nanbo and Zhang, Le and Kuja-Halkola, Ralf and D'Onofrio, Brian M and Brikell, Isabell and Lichtenstein, Paul and Cortese, Samuele and Larsson, Henrik and Chang, Zheng},
  title = {ADHD Pharmacotherapy and Mortality in Individuals With ADHD},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {10},
  pages = {850},
  doi = {10.1001/jama.2024.0851}
}
Kostenlos starten →